Safety and efficacy of an inhaled epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (BIBW 2948) in COPD
P. Woodruff, J. Hohlfeld, N. Krug, M. Dransfeld, R. Sutherland, G. Criner, V. Kim, A. Prasse, C. Nivens, K. Tetzlaff, J. Fahy (San Francisco, Birmingham, Denver, Philadelphia, Ridgefield, United States Of America; Hannover, Freiburg, Germany)
Source: Annual Congress 2009 - New drugs for airways disease
Session: New drugs for airways disease
Session type: Oral Presentation
Number: 1803
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Woodruff, J. Hohlfeld, N. Krug, M. Dransfeld, R. Sutherland, G. Criner, V. Kim, A. Prasse, C. Nivens, K. Tetzlaff, J. Fahy (San Francisco, Birmingham, Denver, Philadelphia, Ridgefield, United States Of America; Hannover, Freiburg, Germany). Safety and efficacy of an inhaled epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (BIBW 2948) in COPD. Eur Respir J 2009; 34: Suppl. 53, 1803
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: